How did we get from having HIV activists chaining themselves to a desk in Burroughs Wellcome offices to having 65 HIV community activists travel from across the US to meet with GSK clinical and commercial leaders in Denver this year? It was not easy.
The cooperative relationship that GSK has developed with the HIV community over the last 20 years parallels the company's successes in helping support the battle against HIV. Successes like providing the first treatment for AIDS, developing an effective therapy to dramatically reduce mother-to-child transmission, and providing the first fixed-dose combination treatment for HIV were all brought to patients by GSK scientists.
We've found that sitting down and engaging in two-way conversations with activists was a critical and productive step in helping us understand the needs of our patients.
This year was the 11th HIV Summer Summit hosted by GSK. Sixty-five activists, advocates, educators, and writers met with us in this annual event, which provides a forum for scientific exchange and education on issues that affect the treatment and lives of people living with HIV.
We recently announced that we're joining with Pfizer to form a new company focused exclusively on HIV and we received a lot of direct, candid feedback from the community regarding what they want to see from a new HIV company.
We've been involved with HIV since the epidemic started. And our commitment to the community has never been stronger.